US5919455A
(en)
*
|
1993-10-27 |
1999-07-06 |
Enzon, Inc. |
Non-antigenic branched polymer conjugates
|
US5951974A
(en)
*
|
1993-11-10 |
1999-09-14 |
Enzon, Inc. |
Interferon polymer conjugates
|
US5908621A
(en)
*
|
1995-11-02 |
1999-06-01 |
Schering Corporation |
Polyethylene glycol modified interferon therapy
|
DE69632062T2
(de)
|
1995-11-02 |
2004-11-18 |
Schering Corp. |
Kontinuierliche, niedrigdosierte zytokine-infusionstherapie
|
US5985263A
(en)
*
|
1997-12-19 |
1999-11-16 |
Enzon, Inc. |
Substantially pure histidine-linked protein polymer conjugates
|
US5981709A
(en)
*
|
1997-12-19 |
1999-11-09 |
Enzon, Inc. |
α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
|
CO5080738A1
(es)
*
|
1998-03-26 |
2001-09-25 |
Schering Corp |
Formulaciones para la proteccion de conjugados de peginter- feron alfa
|
US6180096B1
(en)
|
1998-03-26 |
2001-01-30 |
Schering Corporation |
Formulations for protection of peg-interferon alpha conjugates
|
SK286654B6
(sk)
*
|
1998-04-28 |
2009-03-05 |
Laboratoires Serono Sa |
Spôsob postupného pripájania polyetylénglykolových častí a použitie PEG-polypeptidových konjugátov vyrobených týmto spôsobom
|
ES2172288T3
(es)
|
1998-05-15 |
2002-09-16 |
Schering Corp |
Terapia de combinacion que comprende ribavirina e interferon alfa en pacientes que no han sido sometidos a tratamiento antiviral y que tienen infeccion cronica de hepatitis c.
|
PL192364B1
(pl)
*
|
1998-06-08 |
2006-10-31 |
Hoffmann La Roche |
Zastosowanie koniugatu PEG-IFN-α 2A w połączeniu z rybawiryną
|
US6277830B1
(en)
*
|
1998-10-16 |
2001-08-21 |
Schering Corporation |
5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
|
IL129299A0
(en)
*
|
1999-03-31 |
2000-02-17 |
Mor Research Applic Ltd |
Monoclonal antibodies antigens and diagnosis of malignant diseases
|
US6605273B2
(en)
|
1999-04-08 |
2003-08-12 |
Schering Corporation |
Renal cell carcinoma treatment
|
DE60020444T2
(de)
|
1999-04-08 |
2006-05-04 |
Schering Corp. |
Melanoma Therapie
|
US6362162B1
(en)
|
1999-04-08 |
2002-03-26 |
Schering Corporation |
CML Therapy
|
CO5170411A1
(es)
*
|
1999-04-08 |
2002-06-27 |
Schering Corp |
Terapia para la leucemia mielocitica cronica
|
US6923966B2
(en)
|
1999-04-08 |
2005-08-02 |
Schering Corporation |
Melanoma therapy
|
CZ299516B6
(cs)
*
|
1999-07-02 |
2008-08-20 |
F. Hoffmann-La Roche Ag |
Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
|
US6313143B1
(en)
*
|
1999-12-16 |
2001-11-06 |
Hoffmann-La Roche Inc. |
Substituted pyrroles
|
BR0107561A
(pt)
|
2000-01-10 |
2002-11-19 |
Maxygen Holdings Ltd |
Polipeptìdios ou conjugados entre polipeptìdios que exibem atividade (g-csf), métodos de preparação dos mesmos e seus usos
|
EP1251866A1
(en)
*
|
2000-01-24 |
2002-10-30 |
Schering Corporation |
Combination of temozolomide and pegylated interferon-alpha for treating cancer
|
EP1908477A3
(en)
*
|
2000-01-24 |
2008-06-11 |
Schering Corporation |
Combination of temozolomide and pegylated interferon-alpha for treating cancer
|
EP1257295B1
(en)
|
2000-02-11 |
2009-04-15 |
Bayer HealthCare LLC |
Factor vii or viia-like molecules
|
US6476062B2
(en)
|
2000-03-30 |
2002-11-05 |
Schering Corporation |
Chemokine receptor antagonists
|
US6777387B2
(en)
|
2000-03-31 |
2004-08-17 |
Enzon Pharmaceuticals, Inc. |
Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same
|
US6756037B2
(en)
|
2000-03-31 |
2004-06-29 |
Enzon, Inc. |
Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups
|
EP1282632A1
(en)
|
2000-04-20 |
2003-02-12 |
Schering Corporation |
Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
|
DE60135393D1
(de)
|
2000-06-30 |
2008-09-25 |
Zymogenetics Inc |
Allelische Variante des Interferon-ähnlichen Proteins Zcyto21
|
DE60236796D1
(de)
|
2001-01-30 |
2010-08-05 |
Kyowa Hakko Kirin Co Ltd |
Verzweigte polyalkylenglykole
|
SK11882003A3
(sk)
|
2001-02-27 |
2004-03-02 |
Maxygen Aps |
Variant štandardného ľudského interferónu ß, nukleotidová sekvencia kódujúca tento variant, expresný vektor a hostiteľská bunka s jej obsahom, farmaceutický prostriedok s obsahom uvedeného variantu a jeho použitie
|
DE10112825A1
(de)
|
2001-03-16 |
2002-10-02 |
Fresenius Kabi De Gmbh |
HESylierung von Wirkstoffen in wässriger Lösung
|
ATE371680T1
(de)
*
|
2002-01-16 |
2007-09-15 |
Biocompatibles Uk Ltd |
Polymerkonjugate
|
KR100888371B1
(ko)
*
|
2002-01-17 |
2009-03-13 |
동아제약주식회사 |
가지 달린 고분자 유도체와 인터페론 결합체를 포함하는 항바이러스제
|
DE10209821A1
(de)
|
2002-03-06 |
2003-09-25 |
Biotechnologie Ges Mittelhesse |
Kopplung von Proteinen an ein modifiziertes Polysaccharid
|
DE10209822A1
(de)
|
2002-03-06 |
2003-09-25 |
Biotechnologie Ges Mittelhesse |
Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
|
AU2003240439B2
(en)
|
2002-06-21 |
2009-05-21 |
Novo Nordisk Health Care Ag |
Pegylated factor VII glycoforms
|
WO2004012773A1
(en)
|
2002-07-24 |
2004-02-12 |
F. Hoffmann-La Roche Ag |
Polyalkylene glycol acid additives
|
EP1681303B1
(en)
*
|
2002-09-11 |
2013-09-04 |
Fresenius Kabi Deutschland GmbH |
HASylated polypeptides, especially HASylated erythropoietin
|
ES2214166T1
(es)
*
|
2002-09-11 |
2004-09-16 |
Fresenius Kabi Deutschland Gmbh |
Polipeptidos has-ilados, especialmente, eriptropoyetina has-ilada.
|
CN100348618C
(zh)
*
|
2002-09-11 |
2007-11-14 |
弗雷泽纽斯卡比德国有限公司 |
生产羟烷基淀粉衍生物的方法
|
DE60323756D1
(de)
|
2002-10-08 |
2008-11-06 |
Fresenius Kabi De Gmbh |
Pharmazeutisch aktive oligosaccharid-conjugate
|
EP1565205A4
(en)
*
|
2002-11-18 |
2006-07-05 |
Maxygen Inc |
INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES
|
US7314613B2
(en)
|
2002-11-18 |
2008-01-01 |
Maxygen, Inc. |
Interferon-alpha polypeptides and conjugates
|
GB0301014D0
(en)
*
|
2003-01-16 |
2003-02-19 |
Biocompatibles Ltd |
Conjugation reactions
|
CA2458085A1
(en)
|
2003-03-21 |
2004-09-21 |
F. Hoffmann-La Roche Ag |
Transcriptional activity assay
|
WO2005014655A2
(en)
|
2003-08-08 |
2005-02-17 |
Fresenius Kabi Deutschland Gmbh |
Conjugates of hydroxyalkyl starch and a protein
|
EP1673387B1
(en)
|
2003-10-10 |
2010-09-15 |
Novo Nordisk A/S |
Il-21 derivatives
|
ES2428358T3
(es)
|
2003-10-17 |
2013-11-07 |
Novo Nordisk A/S |
Terapia de combinación
|
WO2005074524A2
(en)
|
2004-02-02 |
2005-08-18 |
Ambrx, Inc. |
Modified human interferon polypeptides and their uses
|
CN100355784C
(zh)
*
|
2004-02-12 |
2007-12-19 |
江苏恒瑞医药股份有限公司 |
聚乙二醇修饰α-干扰素1b的制备方法
|
AU2005225513B2
(en)
|
2004-03-11 |
2012-01-12 |
Fresenius Kabi Deutschland Gmbh |
Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
|
MXPA06013412A
(es)
*
|
2004-05-19 |
2007-01-23 |
Maxygen Inc |
Polipeptidos de interferon-alfa y conjugados.
|
US7632924B2
(en)
|
2004-06-18 |
2009-12-15 |
Ambrx, Inc. |
Antigen-binding polypeptides and their uses
|
WO2006004959A2
(en)
*
|
2004-06-30 |
2006-01-12 |
Egen Corporation |
Pegylated interferon alpha-1b
|
KR20070045244A
(ko)
|
2004-08-12 |
2007-05-02 |
쉐링 코포레이션 |
안정한 페길화된 인터페론 제형
|
EP2284191A3
(en)
|
2004-12-22 |
2011-07-20 |
Ambrx, Inc. |
Process for the preparation of hGH
|
WO2006102659A2
(en)
*
|
2005-03-23 |
2006-09-28 |
Nektar Therapeutics Al, Corporation |
CONJUGATES OF AN hGH MOIETY AND A POLYMER
|
KR20080019619A
(ko)
|
2005-05-18 |
2008-03-04 |
맥시겐, 인크. |
개량된 인터페론-알파 폴리펩티드
|
EP1893632B1
(en)
|
2005-06-17 |
2015-08-12 |
Novo Nordisk Health Care AG |
Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
|
KR20080037656A
(ko)
*
|
2005-06-20 |
2008-04-30 |
펩젠 코포레이션 |
저독성의 장시간 순환하는 사람 인터페론-알파 유사체 및인터페론 타우의 키메라
|
JP4261531B2
(ja)
|
2005-09-06 |
2009-04-30 |
株式会社Nrlファーマ |
ラクトフェリン複合体及びその製造方法
|
KR20080079643A
(ko)
|
2005-11-16 |
2008-09-01 |
암브룩스, 인코포레이티드 |
비-천연 아미노산을 포함하는 방법 및 조성물
|
CN101002944B
(zh)
*
|
2006-01-17 |
2012-07-25 |
中国科学院过程工程研究所 |
支链聚乙二醇-干扰素结合物及其制备方法
|
CN101002945B
(zh)
|
2006-01-20 |
2012-09-05 |
清华大学 |
一种用于肿瘤治疗的新型复合物
|
CN100475270C
(zh)
|
2006-01-20 |
2009-04-08 |
清华大学 |
一种治疗肿瘤的药物及其应用
|
WO2007132882A1
(ja)
|
2006-05-16 |
2007-11-22 |
Tokyo Metropolitan Organization For Medical Research |
Hcv感染症を治療または予防するための医薬組成物
|
US20090252720A1
(en)
|
2006-05-24 |
2009-10-08 |
Novo Nordisk Health Care Ag |
Prolonged FIX Analogues and Derivatives
|
MX2009002523A
(es)
|
2006-09-08 |
2009-03-20 |
Ambrx Inc |
Polipeptido de plasma humano modificado o andamios fc y sus usos.
|
CA2662753C
(en)
|
2006-09-08 |
2016-02-23 |
Ambrx, Inc. |
Hybrid suppressor trna for vertebrate cells
|
CN1966547B
(zh)
*
|
2006-11-06 |
2011-11-09 |
中国药科大学 |
双链结构的聚乙二醇衍生物的制备及其与药物分子的结合
|
AU2007316875A1
(en)
*
|
2006-11-07 |
2008-05-15 |
Dsm Ip Assets B.V. |
Carbamate, thiocarbamate or carbamide comprising a biomolecular moiety
|
KR101079993B1
(ko)
|
2006-11-17 |
2011-11-04 |
동아제약주식회사 |
폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체
|
CN101219219B
(zh)
|
2007-01-10 |
2013-02-13 |
北京普罗吉生物科技发展有限公司 |
包含血管抑素或其片段的复合物、其制备方法及应用
|
JP5515224B2
(ja)
|
2007-02-28 |
2014-06-11 |
日油株式会社 |
多分岐鎖ポリオキシアルキレン誘導体
|
ATE554785T1
(de)
|
2007-03-30 |
2012-05-15 |
Ambrx Inc |
Modifizierte fgf-21 polypeptide und ihre verwendung
|
CL2008002399A1
(es)
*
|
2007-08-16 |
2009-01-02 |
Pharmaessentia Corp |
Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
|
ATE548382T1
(de)
|
2007-09-04 |
2012-03-15 |
Biosteed Gene Expression Tech Co Ltd |
Polyethylenglykolmodifiziertes interferon alpha 2b und herstellungsverfahren und anwendungen davon
|
ES2386575T3
(es)
|
2007-09-04 |
2012-08-23 |
Biosteed Gene Expression Tech. Co., Ltd. |
Interferón alfa 2a modificado por polietilenglicol, su proceso de síntesis y su aplicación
|
KR101656107B1
(ko)
|
2007-11-20 |
2016-09-08 |
암브룩스, 인코포레이티드 |
변형된 인슐린 폴리펩티드 및 이의 용도
|
EP2070950A1
(en)
|
2007-12-14 |
2009-06-17 |
Fresenius Kabi Deutschland GmbH |
Hydroxyalkyl starch derivatives and process for their preparation
|
WO2009090056A2
(en)
*
|
2008-01-18 |
2009-07-23 |
F. Hoffmann-La Roche Ag |
Purification of not-glycosylated polypeptides
|
WO2009095479A2
(en)
*
|
2008-02-01 |
2009-08-06 |
Ascendis Pharma As |
Prodrug comprising a self-cleavable linker
|
MX344166B
(es)
|
2008-02-08 |
2016-12-07 |
Ambrx Inc |
Leptina-polipeptidos modificados y sus usos.
|
BRPI0822530B1
(pt)
|
2008-04-03 |
2022-03-22 |
Biosteed Gene Expression Tech. Co., Ltd |
Método de preparação de um hormônio de crescimento humano glicolado por polietileno (modificado por peg), hormônio do crescimento humano modificado por peg de menor peso molecular aparente e seu uso, preparação de hormônio do crescimento humano modificado por peg de menor peso molecular aparente e seu método de preparação e composição
|
EP2279007B1
(en)
*
|
2008-04-29 |
2016-05-18 |
Ascendis Pharma Growth Disorders Division A/S |
Pegylated recombinant human growth hormone compounds
|
TW201010692A
(en)
|
2008-06-19 |
2010-03-16 |
Public Univ Corp Nagoya City Univ |
Pharmaceutical composition for treatment or prevention of hbv infection
|
UA103492C2
(ru)
|
2008-07-08 |
2013-10-25 |
Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем |
Ингибиторы пролиферации и активации переносчика сигнала и активатора транскрипции (stats)
|
NZ600382A
(en)
|
2008-07-23 |
2013-11-29 |
Ambrx Inc |
Modified bovine G-CSF polypeptides and their uses
|
NZ607477A
(en)
|
2008-09-26 |
2014-09-26 |
Ambrx Inc |
Non-natural amino acid replication-dependent microorganisms and vaccines
|
EP3216800A1
(en)
|
2008-09-26 |
2017-09-13 |
Ambrx, Inc. |
Modified animal erythropoietin polypeptides and their uses
|
IT1399351B1
(it)
|
2009-06-16 |
2013-04-16 |
Fidia Farmaceutici |
Procedimento per la sintesi di coniugati di glicosamminoglicani (gag) con molecole biologicamente attive, coniugati polimerici e usi relativi
|
WO2011014882A1
(en)
|
2009-07-31 |
2011-02-03 |
Medtronic, Inc. |
CONTINUOUS SUBCUTANEOUS ADMINISTRATION OF INTERFERON-α TO HEPATITIS C INFECTED PATIENTS
|
KR20120106942A
(ko)
|
2009-10-30 |
2012-09-27 |
베링거 인겔하임 인터내셔날 게엠베하 |
Bi201335, 인터페론 알파 및 리바비린을 포함하는 hcv 병용 치료요법을 위한 투여 용법
|
CN107674121A
(zh)
|
2009-12-21 |
2018-02-09 |
Ambrx 公司 |
经过修饰的牛促生长素多肽和其用途
|
US20120283172A1
(en)
|
2009-12-21 |
2012-11-08 |
Ambrx, Inc. |
Modified porcine somatotropin polypeptides and their uses
|
AU2011222883B2
(en)
|
2010-03-05 |
2016-05-26 |
Omeros Corporation |
Chimeric inhibitor molecules of complement activation
|
US20120135912A1
(en)
|
2010-05-10 |
2012-05-31 |
Perseid Therapeutics Llc |
Polypeptide inhibitors of vla4
|
CA2803093A1
(en)
|
2010-06-24 |
2011-12-29 |
Panmed Ltd. |
Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
|
RU2447083C1
(ru)
*
|
2010-07-20 |
2012-04-10 |
Закрытое Акционерное Общество "Биокад" |
НОВЫЙ ФУНКЦИОНАЛЬНО АКТИВНЫЙ ВЫСОКООЧИЩЕННЫЙ СТАБИЛЬНЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА α С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, С УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, С ПРОЛОНГИРОВАННЫМ БИОЛОГИЧЕСКИМ ДЕЙСТВИЕМ, ПРИГОДНЫЙ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ
|
CA2805564A1
(en)
|
2010-08-05 |
2012-02-09 |
Stefan Jenewein |
Anti-mhc antibody anti-viral cytokine fusion protein
|
WO2012024452A2
(en)
|
2010-08-17 |
2012-02-23 |
Ambrx, Inc. |
Modified relaxin polypeptides and their uses
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
AR083006A1
(es)
|
2010-09-23 |
2013-01-23 |
Lilly Co Eli |
Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
|
WO2012146630A1
(en)
|
2011-04-29 |
2012-11-01 |
F. Hoffmann-La Roche Ag |
N-terminal acylated polypeptides, methods for their production and uses thereof
|
CN102229667A
(zh)
*
|
2011-06-03 |
2011-11-02 |
北京伟嘉人生物技术有限公司 |
一种聚乙二醇修饰的猪α-干扰素及其制备方法和应用
|
AR087020A1
(es)
|
2011-07-01 |
2014-02-05 |
Bayer Ip Gmbh |
Polipeptidos de fusion de relaxina y usos de los mismos
|
CA2843495A1
(en)
|
2011-08-03 |
2013-02-07 |
Cytheris |
Hcv immunotherapy
|
WO2013137869A1
(en)
|
2012-03-14 |
2013-09-19 |
Boehringer Ingelheim International Gmbh |
Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
|
WO2013143581A1
(en)
|
2012-03-28 |
2013-10-03 |
Boehringer Ingelheim International Gmbh |
Combination therapy for treating hcv infection in specific patient subgenotype sub-population
|
SI2859017T1
(sl)
|
2012-06-08 |
2019-05-31 |
Sutro Biopharma, Inc. |
Protitelesa, ki vsebujejo specifične nenaravne aminokislinske ostanke, postopki njihove priprave in postopki njihove uporabe
|
EP3135690A1
(en)
|
2012-06-26 |
2017-03-01 |
Sutro Biopharma, Inc. |
Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
PL3584255T3
(pl)
|
2012-08-31 |
2022-05-16 |
Sutro Biopharma, Inc. |
Modyfikowane aminokwasy zawierające grupę azydkową
|
EA023323B1
(ru)
*
|
2013-03-28 |
2016-05-31 |
Илья Александрович МАРКОВ |
Разветвленный ацилазидный пегилирующий агент, способ его получения и способ получения пегилированного интерферона
|
EA021610B1
(ru)
*
|
2013-03-28 |
2015-07-30 |
Илья Александрович МАРКОВ |
Жидкое противовирусное лекарственное средство
|
EA022617B1
(ru)
*
|
2013-03-28 |
2016-02-29 |
Илья Александрович МАРКОВ |
Монопегилированный интерферон-альфа разветвленной структуры и фармацевтическая композиция для приготовления лекарственного средства, обладающего активностью интерферона-альфа
|
US9764039B2
(en)
|
2013-07-10 |
2017-09-19 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
US9840493B2
(en)
|
2013-10-11 |
2017-12-12 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
EP2907512A1
(en)
|
2014-02-14 |
2015-08-19 |
Commissariat A L'energie Atomique Et Aux Energies Alternatives |
Inhibitors of MMP-12 as antiviral Agents
|
RU2554761C1
(ru)
*
|
2014-05-13 |
2015-06-27 |
Закрытое акционерное общество "Сибирский центр фармакологии и биотехнологии" |
Противоэнтеровирусное и иммуностимулирующее средство
|
SI3412302T1
(sl)
|
2014-10-24 |
2021-09-30 |
Bristol-Myers Squibb Company |
Modificirani FGF-21 polipeptidi in njihova uporaba
|
EP3215193B1
(en)
|
2014-11-06 |
2023-10-04 |
PharmaEssentia Corporation |
Dosage regimen for pegylated interferon
|
CN108135979A
(zh)
|
2015-11-03 |
2018-06-08 |
豪夫迈·罗氏有限公司 |
Hbv衣壳组装抑制剂和干扰素的组合疗法
|
CN106749608B
(zh)
*
|
2015-11-18 |
2021-10-15 |
石药集团中奇制药技术(石家庄)有限公司 |
干扰素α缀合物
|
WO2018087345A1
(en)
|
2016-11-14 |
2018-05-17 |
F. Hoffmann-La Roche Ag |
COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
|
AU2018219283B2
(en)
|
2017-02-08 |
2022-05-19 |
Bristol-Myers Squibb Company |
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
|
RU2678332C1
(ru)
|
2017-09-08 |
2019-01-28 |
Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ") |
Пегилированный интерферон лямбда, обладающий высокой биодоступностью при пероральном применении, и способ его получения
|
WO2020056066A1
(en)
|
2018-09-11 |
2020-03-19 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and their uses
|
CN113366015A
(zh)
|
2018-10-19 |
2021-09-07 |
Ambrx公司 |
白细胞介素-10多肽缀合物、其二聚体及其用途
|
CN113660957A
(zh)
|
2019-02-12 |
2021-11-16 |
Ambrx公司 |
包含抗体-tlr激动剂缀合物的组合物、方法和用途
|
AU2021233909A1
(en)
|
2020-03-11 |
2022-09-29 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and methods of use thereof
|
KR20230073200A
(ko)
|
2020-08-20 |
2023-05-25 |
암브룩스, 인코포레이티드 |
항체-tlr 작용제 접합체, 그 방법 및 용도
|
JP2024512775A
(ja)
|
2021-04-03 |
2024-03-19 |
アンブルックス,インコーポレイテッド |
抗her2抗体薬物コンジュゲート及びその使用
|